Drug Type Small molecule drug |
Synonyms HS-10529 |
Target |
Action inhibitors |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| KRAS G12D mutation Solid Tumors | Phase 1 | China | 03 Jun 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 15 May 2025 | |
| KRAS G12D mutation Colorectal cancer | IND Approval | China | 19 Mar 2026 | |
| KRAS G12D mutation Non-small cell lung cancer | IND Approval | China | 19 Mar 2026 | |
| KRAS G12D mutation pancreatic cancer | IND Approval | China | 19 Mar 2026 |





